Introduction
Epilepsy is one of the most common serious neurological disorders with a high incidence and prevalence throughout the world [1] . It had been recognized as one of the most important health threats and estimated to affect about 65 million individuals worldwide with almost 40 thousands new cases of epilepsy diagnosed each year [2] . Moreover, about 30% epilepsy patients do not have good prognosis despite appropriate therapy with antiepileptic drugs [2] . Epilepsy is a complex disease caused by multiple genetic and environmental factors. Previous epidemiological and experimental studies have identified several risk factors in the pathogenesis of epilepsy, including structural neurologic disorders, infection, hypoxia, metabolism, and toxicity [3, 4] . Recently, genomics and epigenetics have generated many new candidate biomarkers of epilepsy [5] [6] [7] .microRNAs (miRNAs) are a class of small, single-stranded, non-proteincoding RNA gene products of about 21-to 24-nucleotide-long that can regulate gene expression by base pairing with target mRNAs, leading to mRNA degradation or translational repression [8] . Recent emerging evidences support a role of miRNAs in regulating a variety of epilepsy biologic processes, such as inflammation [9, 10] , apoptosis Purpose: MicroRNA (miRNA), functions as gene regulators, plays crucial roles in pathogenesis of epilepsy. We hypothesized that single nucleotide polymorphisms (SNPs) in miRNA may be associated with childhood epilepsy. Method: We first genotyped the selected four SNPs (miR-146a rs57095329, miR-149 rs2292832, miR196a2 rs11614913, and miR-499 rs3746444) in 267 paired childhood epilepsy patients and controls using the TaqMan assay, and evaluated the associations of the four SNPs with the risk of epilepsy. In addition, we evaluated the associations of these SNPs with drug-resistance in 95 drug-resistant and 172 drug-responsive epilepsy patients. Furthermore, the genotype-phenotype correlation was assessed in 95 drug-resistant epilepsy patients. Results: The selected four SNPs (miR-146a rs57095329, miR-149 rs2292832, miR-196a2 rs11614913, and miR-499 rs3746444) were not significantly different between epilepsy patients and controls (P > 0.05 for all). However, the miR-146a rs57095329 A/G genotypes were significantly associated with increased drug-resistance risk of epilepsy patients in allelic comparison (OR = 2.363, 95%CI = 1.608-3.472, P < 0.001), heterozygote model (OR = 2.341, 95%CI = 1.301-4.211, P = 0.005), homozygote model (OR = 1.791, 95%CI = 1.239-2.589, P = 0.002), dominant model (OR = 2.625, 95%CI = 1.558-4.425, P < 0.001), and recessive model (OR = 2.336, 95%CI = 1.166-4.673, P = 0.017). Moreover, subjects with the rs57095329 GG genotype had significantly higher NHS3 score than subjects with AA genotype (P < 0.001) and AG genotype (P = 0.013) in the drug resistant patients. Conclusion: miR-146a rs57095329 polymorphism might be involved in the genetic susceptibility to drug-resistance and seizure severity in childhood epilepsy patients.
ß 2016 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved. [11, 12] , neuronal differentiation [13] , synaptic signal transmission [14] , axonal guidance and synaptic plasticity [15] . MiRNAs are also aberrantly expressed in epilepsy, and specific miRNAs have been shown to be associated with the risk of epilepsy and could be used as biomarkers for epilepsy [16, 17] . Although the regulation of miRNA expression and maturation remains largely unknown, previous studies have suggested singlenucleotide polymorphisms (SNPs) may affect the levels of mature miRNAs and interfere with thousands of target mRNAs stability and translation [18] . Therefore, the identification of functional SNPs in miRNAs sequences may lead to a class of candidate biomarkers for related diseases. Recently, lots of studies have investigated the association of four SNPs rs57095329, rs2292832, rs11614913, and rs3746444 in precursor miRNAs sequences (miR146a, miR-149, miR-196a2, and miR-499, respectively) with neurodegenerative disorders, such as Parkinson's disease [19] , multiple sclerosis [20] , and Alzheimer's disease [21] . Interestingly, the four miRNAs also regulate gene related to inflammation pathways including tumor necrosis factor-a (TNF-a), Toll-like receptor signaling, and ensuing cytokine response [22, 23] . In the present study, we hypothesized that the SNPs (rs57095329, rs2292832, rs11614913, and rs3746444) in precursor miRNAs sequences may also contribute to epilepsy risk. To test this hypothesis, we genotyped and analyzed the four SNPs in a hospital-based case-control studies (267 paired childhood epilepsy patients and controls) in a Chinese population.
Materials and methods

Study population
The case-control study was composed of 267 childhood epilepsy patients and 267 age and sex matched healthy controls. All subjects were unrelated Chinese people with the ethnic Han. The epilepsy patients who were hospitalized at the Department of Neurology, Nanjing Children's Hospital Affiliated to Nanjing Medical University in Nanjing (Nanjing, China) from March 2010 to June 2015 were consecutively recruited. All patients underwent clinical electro-encephalography (EEG) and magnetic resonance imaging (MRI) examination, and the diagnosis of childhood epilepsy was based on the guidelines proposed by the International League Against Epilepsy. Patients with unreliable seizure history, severe systemic/co-morbidities or other brain diseases were excluded from this study. The seizure types and symptoms were valued and provided by the experienced pediatric neurologists. Moreover, according to treatment effects of antiepileptic drugs (AEDs), the epilepsy patients were divided into drug resistant group and drug responsive group. Briefly, patients who had no change or less than 50% reduction in the seizure frequency for AEDs treatment or underwent epilepsy surgery were classified as having drug-resistant epilepsy; otherwise, patients were classified as drug-responsive epilepsy. Subjects without medical history of seizures or neuropsychiatric disorders were selected as controls during a physical health examination at the hospital, and they were matched with the patients by age, sex, and area of residence. Fasting peripheral venous blood samples were collected in sterile tubes with EDTA-Na2 anticoagulants from the patients on the morning of the day after admission, and from controls on the day of physical health examination. All blood samples were stored at À80 8C until use.
The demographic characteristics of the participants were collected from their parents by trained interviewer using structured questionnaires. This study was approved by the Ethics Committee of Nanjing Children's Hospital Affiliated to Nanjing Medical University, and written informed consent was also obtained from each participant's parents.
Genotyping of miRNA polymorphisms
A 200-ml EDTA-Na2 anticoagulants venous blood samples was taken for DNA extraction and genotyping. Genomic DNA of each participant was extracted from blood samples using commercially DNA isolation kit (Tiangen, China) according to the manufacturer's instructions. Genotyping of the four miRNA polymorphisms (rs57095329, rs2292832, rs11614913, and rs3746444) was performed with TaqMan SNP Genotyping Assay (Applied Biosystems) by using the 384-well ABI 7900HT Real-Time PCR System according to the manufacture's instructions (Applied Biosystems) in 267 epilepsy patients and 267 controls. The sequences of primer and probe for each SNP are available on request. Three negative (water) control samples and 3 duplicates were included in each 96 well assay plate as a quality control measure. At the same time, genotypes analysis was performed in a blind fashion. Additionally, 10% of the samples were randomly selected for repeated genotyping for confirmation, and the results were 100% concordant.
Statistical analysis
All statistical analyses were performed using SPSS 21.0 software (Statistical Package for the Social Sciences, Chicago, USA) and P < 0.05 was considered significant (two-tailed). The Pearson chisquare test was conducted for assessing differences in sex distribution and clinical characteristics between two groups. All the SNPs were detected for the Hardy-Weinberg equilibrium among the controls using a Pearson chi-square test with one degree of freedom. The continuous variables such as current age, age of seizure onset, and NHS3 score were tested for the normal distribution by the One-Sample Kolmogorov-Smirnov test and were expressed as mean AE standard deviation (SD). Differences in the continuous variables between two groups were evaluated by the independent samples t-test. The differences in NHS3 score among genotypes in drug-resistant patients were compared by one-way analysis of covariance and Student Newman Keuls test. The multiple logistic regression analysis was used to evaluate associations between the frequency of miRNA polymorphisms and epilepsy risk with adjustment for age and sex, and to assess associations between the frequency of miRNA polymorphisms and drug-resistant risk with adjustment for age, sex, onset age, seizure types, epileptic foci, and etiology.
Results
Clinical characteristics
A total of 267 epilepsy patients (177 males and 90 females; mean age 7.5 AE 3.4 years old) and 267 unrelated gender and agematched controls (180 males and 87 females; mean age 7.8 AE 3.2 years old) were analyzed in our study. The distributions of the age and gender did not significantly differ between the epilepsy patients and controls (P = 0.294 and 0.783, respectively). The demographic and clinical characteristics of epilepsy patients are summarized in Table 1 . There were no statistically significant differences between drug resistant and responsive epilepsy patients in terms of the frequency distribution of age, sex, seizure types, epileptic foci and etiology. Compared to the drug responsive patients, the drug resistant patients had earlier age of onset (3.4 versus 4.0 years, P = 0.028). Of the 95 drug resistant patients, 14 (14.7%) were daily seizure, 17 (17.9%) > once a week seizure, 40 (42.1%) 1-4 times per month seizure, and 24 (25.3%) < once a month seizure. Meanwhile, the mean NHS3 score of the drug resistant patients was 12.89 AE 3.21 (Fig. 1). 
Association of the miRNA polymorphisms with the risk of epilepsy
The genotype of the four miRNA polymorphisms (rs57095329, rs2292832, rs11614913, and rs3746444) in epilepsy patients and controls are shown in Table 2 . The miRNA polymorphism frequencies in controls are consistent with the Hardy-Weinberg equilibrium expectations for rs57095329 (HWE P = 0.250), rs2292832 (HWE P = 0.785), rs11614913 (HWE P = 0.898), and rs3746444 (HWE P = 0.122). However, rs57095329, rs2292832, rs11614913, and rs3746444 polymorphisms were not significantly different between epilepsy patients and controls.
Subtype analysis of epilepsy
In order to examine whether the effect of the four miRNA polymorphisms is confined to drug resistance of epilepsy, we further separated the epilepsy patients into drug resistant group and drug responsive group. Results suggest that epilepsy patients with rs57095329 AG genotype or GG genotype had higher drug resistant risks compare with patients carrying AA genotype (OR = 2.341, 95%CI = 1.301-4.211, P = 0.005; OR = 1.791, 95%CI = 1.239-2.589, P = 0.002; respectively). Rs57095329 showed significant associations in the dominant model (OR = 2.625, 95%CI = 1.558-4.425, P < 0.001) and recessive model (OR = 2.336, 95%CI = 1.166-4.673, P = 0.017). As expected, the G allele of miR146a rs57095329 was also associated with significantly increased risk for drug resistance compared with the A allele (OR = 2.363, 95%CI = 1.608-3.472, P < 0.001). However, none of the genotype of other polymorphisms was significantly associated with the drug resistant risk (P > 0.05 for all). In the drug resistant patients, subjects with the rs57095329 GG genotype had significantly higher NHS3 scores than subjects with AA genotype (P < 0.001) or AG genotype (P = 0.013).
Discussion
In this study, we evaluated the associations between four miRNA polymorphisms and the risk of childhood epilepsy in a Chinese population, and also estimated the effects of miRNA polymorphisms and clinical characteristics. Our findings suggested that subjects carrying G allele of rs57095329 might have increased risk of drug-resistance and seizure severity in childhood epilepsy patients (Table 3) .
Alteration in the expression of miRNAs are known to contribute to the pathogenesis of epilepsy, including inflammation, apoptosis, neuronal differentiation, synaptic signal transmission, axonal guidance and synaptic plasticity [9] [10] [11] [12] [13] [14] [15] . Emerging evidence has indicated miRNAs may be also novel biomarkers for neurological disorders, including Parkinson's disease [19] , multiple sclerosis [20] , Alzheimer's disease [21] , and epilepsy [24] , etc. In 2011, Song and colleagues first conducted miRNAs profiling studies using hippocampus form rat model of temporal lobe epilepsy, and found 23 of 125 detected miRNAs were expressed differentially in temporal lobe epilepsy rats [25] . Later, Kan performed a genomewide miRNA profiling study in human mesial temporal lobe epilepsy, and found miRNAs changes in mesial temporal lobe epilepsy affect the expression of immunomodulatory proteins thereby further facilitating the immune response [26] . Recent, more and more studies have provided compelling evidence that epilepsy is associated with widespread changes to miRNAs expression [7, 17, 27] . Previous studies had demonstrated that the miR-146a, -149, -196a2, and -499 were closely associated with inflammation response [23, [28] [29] [30] , which was considered as one of the pathogenesis of epilepsy. For example, miR-146 is a nuclear factor kB (NF-kB) transactivational target and negatively regulates IRAK1 and TRAF6, and identified as a powerful innate immune and pro-inflammation regulator [31] . Xu and his colleagues have found that miR-149 is a key player of immune modulator for Toll-like receptors signaling pathway [23] . Based on the results, we suspect the four miRNAs have important roles in epilepsy pathogenesis through regulation of inflammation.
Previous studies have suggested that SNPs in pre-miRNA sequences may regulate the processing of mature miRNAs or biding to its target mRNA, and thus result in diverse functional consequences. To date, lots of studies have investigated the association of four SNPs in pri-miRNAs sequences (miR-146a rs57095329, miR-149 rs2292832, miR-196a2 rs11614913, and miR-499 rs3746444) with cancers, asthma, systemic lupus erythematosus, and Alzheimer's disease in Chinese population. Tian and colleagues firstly genotyped four SNPs pri-miRNAs sequences in Chinese population and reported that the miR196a2 rs11614913 SNP can affect mature miR-196a2 expression and binding of maturemiR-196a2 to its target mRNA, and therefore contribute to risk of non-small lung cancer [32] . Luo et al. firstly found rs57095329 SNP in the promoter region of miR-146a and the G allele may increase the risk of systemic lupus erythematosus in Asians by reducing levels of miR-146a [33] . Su and his colleagues investigated that the TT genotype and T allele of rs2292832 were significantly associated with a decreased risk of asthma [34] . Shen et al. evaluated the association between miR-499 rs3746444 polymorphism and esophageal squamous cell carcinoma risk in 1400 patients and 2185 matched controls, and found miR-499 rs3746444 were associated with an increased esophageal squamous cell carcinoma risk [35] . In this study, we genotype the four SNPs in pri-miRNAs sequences (miR-146a rs57095329, miR-149 rs2292832, miR-196a2 rs11614913, and miR-499 rs3746444)in 267 paired childhood epilepsy patients and controls to evaluate the associations of the four SNPs with the risk of epilepsy. However, we found no association between the four SNPs and epilepsy risk in this study. Two recent studies reporting the associations between miR-146a polymorphisms (rs2910164 and rs57095329) and epilepsy susceptibility have been published, consistent with our findings, they did not find that the SNPs of miR-146a were associated with epilepsy [24, 36] . Thus, the four SNPs might have different effects on human diseases in specific organs, and our findings need to be validated in further studies. However, there was a novel finding that miR-146a rs57095329 polymorphism might be involved in the genetic susceptibility to drug-resistance and seizure severity of epilepsy in this study. Consistent with our findings, Cui et al. also found the rs57095329 G allele of miR-146a significantly increased drug-resistant epilepsy risk [36] . The rs57095329 polymorphism can influence mature miR-146a levels by altering the binding affinity of miR-146a for VEts oncogene homologue 1 (Ets-1) [33] . One study has investigated Ets-1 was widely expressed in the cortex and hippocampus and was up-regulated in Alzheimer's disease [37] . Moreover, miR-146a can repress the pro-inflammatory NF-Kb pathway as well as the MAP kinase pathway and acts as a regulator to prevent an excessive inflammatory [38] . Additionally, one study investigated a state of chronic inflammation in epilepsy patients [9] . All of the findings indicated G allele of rs57095329 could influence the miR146a expression level, thus strengthen the chronic inflammation in epilepsy patients, and thereby potentially increasing the drugresistant risk and seizure severity.
The present study has several strengths and limitations. First, this the first study to our knowledge to research four different miRNAs(miR-146a, -149, -196a2, and -499) SNPs and epilepsy risk. Second, we evaluated the associations of these SNPs with drugresistance in 95 drug-resistant and 172 drug-responsive epilepsy patients. Finally, the genotype-phenotype correlation was assessed in drug-resistant epilepsy patients. However, all subjects participated in this study were ethnic Han Chinese, the associations of these SNPs with epilepsy in other ethnic groups also needs further validation by larger prospective studies. Moreover, the clear mechanisms by which the miR-146a rs57095329 polymorphism contributes to drug-resistant risk and seizure severity in epilepsy are still unknown, therefore, the subject warrants further characterization of miR-146a rs57095329 polymorphism in vitro and vivo studies.
In conclusion, our study provided the evidence that that miR146a rs57095329 polymorphism might be involved in the genetic susceptibility to drug-resistance and seizure severity in childhood epilepsy patients. Extensive functional researches and additional well-designed population-based prospective studies with different ethnic groups are warranted to confirmed and extend our findings.
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